NCT00928811View on ClinicalTrials.gov

Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
End Stage Renal Disease
Interventions
DRUG

basiliximab

Simulect 20 mg intravenously day of transplant and day 4

DRUG

basiliximab

Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.

Trial Locations (1)

19102

Drexel University College of Medicine, Philadelphia

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Drexel University College of Medicine

OTHER